Onyx Shuts Down $10 Bln Offer - Presented by: The Aol. On Network

Shares of Onyx Pharmaceutical soaring after it received- and rejected a $10 billion takeover offer from biotech Amgen. Its shares were already up 31 percent over the past 12 months. Onyx says Amgen's offer of $120 a share is too low. That offer represents a premium of 38 percent based on Onyx's closing price on Friday. And Onyx may have a point. Deutsche Bank analyst Robin Karnauskas says in a note: "From our M&A valuation, we expect higher bids for Onyx of at least $140."



Related Videos

Most Popular Videos

Latest Videos


Most Active by Volume

Company Last Sale Change Net / %
HTZ $ 28.639 2.92 ▼ 9.26%
AAPL $ 100.95 0.42 ▲ 0.42%
NOK $ 8.1899 0.17 ▲ 2.12%
FOLD $ 5.869 1.30 ▲ 28.42%
BAC $ 15.43 0.02 ▼ 0.13%
JCP $ 10.425 0.18 ▲ 1.71%
AEO $ 12.64 1.05 ▲ 9.06%
SPLS $ 11.3052 0.31 ▼ 2.71%

As of 8/20/2014, 01:07 PM
More Most Active